Prasad Adusumilli and colleagues have shown that CAR T cells that start to lose power can be revived by immunotherapy drugs given several weeks later. Mesothelioma is a rare cancer that affects the ...

Mesothelioma, a type of lung cancer highly associated with asbestos exposure, has a five-year survival rate of only 10%. Following the CheckMate 743 trial, the dual immune checkpoint inhibitor (ICI) ...

Mesothelioma is a rare type of cancer, most often caused by exposure to asbestos, according to the U.S. Centers for Disease ...

Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

To date, there is no standard therapy for malignant pleural mesothelioma. Historically, surgery is potentially beneficial in patients with low-volume disease, but in patients for whom surgery is not ...

Maintenance treatment with a novel dendritic cell immunotherapy after chemotherapy did not improve survival outcomes for patients with pleural mesothelioma in the phase II/III DENIM study. Over a ...

`S-HERTOGENBOSCH, Netherlands--(BUSINESS WIRE)--Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation to SynKIR-110, an investigational chimeric antigen receptor T-cell ...

AUSTIN, Texas , Oct. 28, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for ...

We are committed to bringing this first-in-class therapy to patients who are in desperate need of new treatment options." VT3989 was recently awarded Orphan Drug Designation and Fast Track Designation ...